EP2139483
Samsettar meðferðir sem fela í sér kínoxalín hemil á PI3K-alfa til notkunar við meðhöndlun á krabbameini
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
8.4.2008EP published:
18.9.2013EP application number:
08742674.8
EP translation filed:
15.11.2013Grant published:
15.12.2013EPO information:
European Patent Register
Max expiry date:
7.4.2028Expiry date:
7.4.2021
Title:
COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER
Timeline
Today
8.4.2008EP application
18.9.2013EP Publication
15.11.2013Translation submitted
15.12.2013Registration published
7.4.2021Expires
Owner
Name:
Exelixis, Inc.Address:
210 East Grand Avenue, 94080, South San Francisco, CA, US
Inventor
Name:
LAMB, PeterAddress:
Oakland, California, US
Name:
MATTHEWS, DavidAddress:
San Francisco, California, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
923164 PDate:
11.4.2007Country:
US
Classification
Categories:
A61K 31/497, A61K 31/498, A61K 31/4985, A61K 31/517, A61K 31/436, A61K 31/555, A61K 31/337, A61K 45/06, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 6.3.2014
Expires: 7.4.2015
Payer: Árnason Faktor
Number: 8
Paid: 9.3.2015
Expires: 7.4.2016
Payer: Árnason Faktor
Number: 9
Paid: 11.3.2016
Expires: 7.4.2017
Payer: Árnason Faktor
Number: 10
Paid: 24.3.2017
Expires: 7.4.2018
Payer: Árnason Faktor
Number: 11
Paid: 9.4.2018
Expires: 7.4.2019
Payer: Árnason Faktor
Number: 12
Paid: 5.4.2019
Expires: 7.4.2020
Payer: Árnason Faktor
Number: 13
Paid: 26.3.2020
Expires: 7.4.2021
Payer: Árnason Faktor ehf.